Courtesy of Benzinga.
Seattle
Genetics, Inc. (Nasdaq: SGEN) today highlighted clinical data with
denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies,
including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute
lymphocytic leukemia (B-ALL), presented at the 57th American
Society of Hematology (ASH) Annual Meeting and Exposition taking place
in Orlando, Florida, December 5-8, 2015. Preclinical data from a novel
antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell
malignancies will also be featured in an oral presentation. About 85
percent of non-Hodgkin lymphomas (NHL) are B-cell lineage, and CD19 is
broadly expressed across all subtypes of B-cell malignancies. These two
ADCs, 19A and SGN-CD19B, both target CD19 and utilize two of Seattle
Genetics’ proprietary payloads, monomethyl auristatin F (MMAF) and a
